Implications for European Competitiveness in Biotechnology
The point of departure of our analysis was the relative weakness of European SME's vis-a-vis American and Japanese companies. With a growth in the figures for numbers of SME's in European biotechnology and stagnation in the figures of U.S.A. it seems that a bridging numerically between Europe and U.S.A. can be observed. However this by no means implies that the technological capability gap is disappering. A first cause for the American strength can be found in the availability of venture capital in U.S.A..